AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cance...(cancertreatment through better understan...),Health

Date:5/13/2008

cancer treatment through better understanding of the molecular biology underlying a patient's tumor. The company's current offerings include a molecular cancer classification assay, Aviara CancerTYPE ID(SM) capable of classifying up to 39 tumor types; Aviara H/I(SM), which predicts endocrine benefit in breast cancer; and Aviara MGI(SM), a molecular grade index to objectively measure tumor grade. Aviara H/I and Aviara MGI are available separately, or can be combined in the Aviara Breast Cancer Index(SM). Additional tests are in development. AviaraDx offers these diagnostic tests to qualified physicians or laboratories through its CLIA-certified, CAP accredited laboratory service operations. For more information, visit http://www.aviaradx.com.

PRESS CONTACT:

Keith McCormick

858/587-5880

kmccormick@aviaradx.com

'/>"/>

SOURCE AviaraDx, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
3. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
7. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
8. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
9. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
10. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
11. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)